These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 2866131)

  • 1. Famotidine: a further development in the modern treatment of peptic ulcer disease. Proceedings of a satellite symposium of the XIIth International Congress of Gastroenterology. Lisbon, September 19, 1984.
    Digestion; 1985; 32 Suppl 1():1-72. PubMed ID: 2866131
    [No Abstract]   [Full Text] [Related]  

  • 2. A review of developments in H2-receptor antagonist therapy: focus on famotidine. Proceedings of an official satellite symposium to the 8th Asian-Pacific Congress on Gastroenterology and the 5th Asian-Pacific Congress of Digestive Endoscopy. Seoul, Korea, 10 October 1988.
    J Int Med Res; 1989; 17 Suppl 1():1A-53A. PubMed ID: 2566538
    [No Abstract]   [Full Text] [Related]  

  • 3. Proceedings of a satellite symposium on famotidine: further developments in H2-receptor antagonist therapy. World Congresses of Gastroenterology meeting. São Paulo, Brazil, 12 September 1986.
    Scand J Gastroenterol Suppl; 1987; 134():1-62. PubMed ID: 2889254
    [No Abstract]   [Full Text] [Related]  

  • 4. Famotidine: clinical applications of a new H2-receptor antagonist. May 16, 1986, Carmel, California.
    Am J Med; 1986 Oct; 81(4B):1-64. PubMed ID: 2877568
    [No Abstract]   [Full Text] [Related]  

  • 5. Famotidine: an evolution in H2 antagonist therapy. Proceedings of a symposium. São Paulo, Brazil, September 7-12, 1986.
    J Clin Gastroenterol; 1987; 9 Suppl 2():1-27. PubMed ID: 2887612
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of upper gastro-intestinal bleeding with the H2-receptor antagonist famotidine.
    Aoki T
    J Int Med Res; 1989; 17 Suppl 1():32A-40A. PubMed ID: 2566542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drugs used in the therapy of peptic ulcer with special reference to H2 receptor blockaders].
    De Natale G; De Natale F; Marino A
    Clin Ter; 1989 Apr; 129(1):3-16. PubMed ID: 2567647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptic ulceration.
    Weir DG
    Br Med J (Clin Res Ed); 1988 Jan; 296(6616):195-200. PubMed ID: 2892567
    [No Abstract]   [Full Text] [Related]  

  • 9. Nizatidine in peptic ulcer disease. Proceeedings of the First International Symposium on Nizatidine. Vienna, 11 and 12 October 1986.
    Scand J Gastroenterol Suppl; 1987; 136():1-88. PubMed ID: 2892250
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical importance of the new H2-antagonists.
    Walt RP
    Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():97-9. PubMed ID: 2566730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma sex steroid transport and histamine H2-receptor antagonists. Clinical implications.
    Berta L; Dusio P; Fortunati N; Fazzari A; Crua MR; Frairia R; Gaidano G
    Ann N Y Acad Sci; 1988; 538():304-12. PubMed ID: 2903712
    [No Abstract]   [Full Text] [Related]  

  • 12. [H2 receptor antagonists and intragastric acidity].
    Dammann HG; Walter TA; Müller P; Simon B
    Dtsch Med Wochenschr; 1984 Nov; 109(46):1767-9. PubMed ID: 6094136
    [No Abstract]   [Full Text] [Related]  

  • 13. Famotidine: postmarketing clinical experience.
    Saigenji K; Fukutomi H; Nakazawa S
    Scand J Gastroenterol Suppl; 1987; 134():34-40. PubMed ID: 2889256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [German language reprints of original papers from the supplement "Nizatidine in peptic ulcer disease" of the Scandinavian Journal of Gastroenterology, Volume 22, Supplement 136, 1987].
    Fortschr Med; 1989 Jan; Spec No 1():1-48. PubMed ID: 2563715
    [No Abstract]   [Full Text] [Related]  

  • 15. Satellite symposium: New therapeutic approach to peptic ulcer disease. 34th annual meeting of the Japanese Society of Gastroenterology.
    Gastroenterol Jpn; 1993 May; 28 Suppl 5():191-201. PubMed ID: 8103024
    [No Abstract]   [Full Text] [Related]  

  • 16. [Ebrotidine: an new alternative in peptic acid diseases].
    Piqué JM
    Med Clin (Barc); 1997 Mar; 108(8):301-3. PubMed ID: 9121207
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacology of H2-receptor antagonists: an overview.
    Schunack W
    J Int Med Res; 1989; 17 Suppl 1():9A-16A. PubMed ID: 2566544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of acid inhibition on Campylobacter pylori.
    Blanco M; Pajares JM; Jimenez ML; Lopez-Brea M
    Scand J Gastroenterol Suppl; 1988; 142():107-9. PubMed ID: 2901784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of famotidine on hepatic hemodynamics and peptic ulcer.
    Ohnishi K; Saito M; Nomura F; Okuda K; Suzuki N; Ohtsuki T; Goto N; Takashi M
    Am J Gastroenterol; 1987 May; 82(5):415-8. PubMed ID: 2883883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical aspects of Kvamatel (famotidine) administration].
    Golochevskaia VS
    Klin Med (Mosk); 1996; 74(1):45-7. PubMed ID: 8649009
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.